Coherus Oncology (CHRS) Projected to Announce Quarterly Earnings on Wednesday

Coherus Oncology (NASDAQ:CHRS) is projected to release its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to announce earnings of ($0.1150) per share and revenue of $14.4060 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 5, 2026 at 5:00 PM ET.

Coherus Oncology (NASDAQ:CHRS) last posted its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.01. Coherus Oncology had a negative return on equity of 198.90% and a net margin of 397.30%.The company had revenue of $12.31 million for the quarter, compared to analyst estimates of $14.22 million. On average, analysts expect Coherus Oncology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Coherus Oncology Stock Performance

Shares of CHRS stock opened at $1.41 on Monday. The stock has a market capitalization of $217.49 million, a PE ratio of 0.84 and a beta of 0.98. The business’s 50 day simple moving average is $1.48 and its 200 day simple moving average is $1.67. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.56 and a quick ratio of 1.52. Coherus Oncology has a one year low of $0.81 and a one year high of $2.62.

Hedge Funds Weigh In On Coherus Oncology

Institutional investors and hedge funds have recently modified their holdings of the business. Quarry LP bought a new stake in shares of Coherus Oncology in the 3rd quarter valued at $26,000. Blair William & Co. IL bought a new position in Coherus Oncology during the fourth quarter worth $27,000. BNP Paribas Financial Markets boosted its stake in Coherus Oncology by 108.2% during the third quarter. BNP Paribas Financial Markets now owns 26,620 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 13,832 shares in the last quarter. Two Sigma Investments LP bought a new position in Coherus Oncology during the third quarter worth $59,000. Finally, Focus Partners Wealth acquired a new stake in Coherus Oncology in the third quarter worth $70,000. 72.82% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Weiss Ratings upgraded shares of Coherus Oncology from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 13th. Guggenheim initiated coverage on shares of Coherus Oncology in a research report on Monday, May 11th. They set a “buy” rating and a $12.00 price objective for the company. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, Coherus Oncology presently has an average rating of “Moderate Buy” and a consensus target price of $8.67.

About Coherus Oncology

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.